In The News

CEOCFO Magazine 2019 Interview with John M. Burke, PhD

In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO of Applied BioMath discusses how Applied BioMath is focused on growing its team of industry leaders to better meet the needs of their biotech and pharma customers using mathematical modeling to de-risk and accelerate drug development. "Our growth plays a role in our brand recognition. Several of our most recent hires, including Alison Betts and Helen Moore, from Pfizer and AstraZeneca, respectively, are leaders in our industry," said Dr. John M.

Verseau Therapeutics engages Applied BioMath, LLC for Systems Pharmacology Modeling in Cancer

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced an agreement with Verseau Therapeutics for the delivery of systems pharmacology pharmacokinetic and target engagement analysis to provide early feasibility assessments for the treatment of cancer. 

Applied BioMath, LLC to Present at Alzheimer's Association International Conference®

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development (R&D), today announced their acceptance to present at the Alzheimer's Association International Conference® (AAIC) occurring July 14-18, 2019 in Los Angeles, CA. Lucia Wille, PhD, Associate Director of Biology at Applied BioMa

Applied BioMath, LLC Announces Marjoleen Nijsen, PhD as Speaker at February Quantitative Systems Pharmacology (QSP) Industry & Academia Symposium

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced the speaker for the QSP Industry & Academia Symposium occurring Thursday, February 28, 2019 from 5:45-8:00 p.m. at the Cambridge Innovation Center, 101 Main Street location, in Cambridge, MA.

Applied BioMath, LLC Announces Collaboration with Codiak BioSciences

Applied BioMath, the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced a collaboration with Codiak BioSciences for the development and delivery of a semi-mechanistic pharmacokinetic, pharmacodynamic (SM-PK/PD) model for exo-STING, a precision-engineered exosome therapeutic targeting the pr

Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Obsidian Therapeutics to provide semi-mechanistic models and analysis services.  Applied BioMath will create semi-mechanistic models, using in vitro and in vivo preclinical data, to aid in dose prediction and knowledge gap identification for Obsidian's promising therapeutic strategy.  "Our Destablizing Domain platform is exceedingly powerful but also ph

Applied BioMath, LLC Announces Participation at Canines-N-Kids Foundation’s Paws for a Cure Research Symposium

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation and sponsorship at Canines-N-Kids Foundation's Paws for a Cure Research Symposium occurring November 12-13, 2018 at the Merck Research Laboratories in Boston, MA. 

 

Applied BioMath, LLC Announces Webinar on using Quantitative Systems Pharmacology (QSP) Approaches to Determine Best in Class Properties in Osteoarthritis

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their upcoming webinar titled "QSP Approaches to Determine Best in Class Properties for Targeted Anabolic Growth Factor to Arthritic Joints" is airing live Thursday, November 8, 2018 at 2p.m. ET / 11a.m. PT.

Applied BioMath, LLC Announces Birgit Schoeberl, PhD as Speaker at October Quantitative Systems Pharmacology (QSP) Industry & Academia Symposium

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced the speaker for the QSP Industry & Academia Symposium occurring Thursday, October 25, 2018 from 5:45-8:00 p.m. at the Cambridge Innovation Center, 101 Main Street location, in Cambridge, MA.

Applied BioMath, LLC Announces Participation at PBSS San Francisco Antibody Drug Conjugate Workshop

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation as a sponsor at the Pharmaceutical and Bioscience Society (PBSS) San Francisco Antibody Drug Conjugate (ADC) workshop being held Wednesday September 12, 2018 at 8:45 a.m. at the SF Bay Area: Foster City Crowne Plaza in San Francisco, CA.